News and Resources

02.25.22

Biohaven Acquires Kv7 Ion Channel Platform For The Treatment Of Epilepsy And Other Neurologic Disorders From Channel Biosciences, A Subsidiary Of Knopp Biosciences

Discover this News
10.20.21

Knopp Biosciences NIH-funded Pain Program Advances to Third Year of HEAL Award to Discover Non-Opioid Treatments for Chronic Pain

Discover this News
05.10.21

Crafting a Cure for Diabetic Neuropathic Pain, Molecule by Molecule (Published by NIH)

Discover this News
10.08.20

Knopp Biosciences NIH-funded Pain Program Advances to Second Year of HEAL Award to Discover Non-Opioid Treatments for Chronic Pain

Discover this News
07.15.20

Knopp Biosciences Receives Rare Pediatric Disease Designation for Kv7 Activator KB-3061 for Treatment of KCNQ2 Epileptic Encephalopathy

Discover this News
12.09.19

Discovery and characterization of KB‐3061: A potent Kv7.2/7.3 ion channel activator for the treatment of KCNQ2 epileptic encephalopathy

Discover this News
12.09.19

KB-3061 Is a Potent Activator of Wild Type KCNQ Channels and Restores Current to KCNQ2 Encephalopathy Variants In Vitro

Discover this News
12.09.19

Knopp Biosciences Presents Data Further Characterizing Its Lead Kv7.2 Activator Drug Candidate For The Treatment Of Kcnq2 Epileptic Encephalopathy At The AES 2019 Annual Meeting

Discover this News
11.27.19

Knopp Biosciences to Present Data Characterizing Its Potassium Channel Activator Candidate for the Treatment of KCNQ2 Epileptic Encephalopathy at the American Epilepsy Society’s 2019 Annual Meeting

Discover this News
1 2 3